U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07773051) titled 'LineMatrix(R) Biological Vascular Graft for the Creation of Arteriovenous Graft' on Aug. 12.
Brief Summary: The study is planned to be conducted at multiple centers, with an intended enrollment of 326 subjects. Protocol-eligible subjects will be randomized in a 1:1 ratio to either the investigational group or the control group. The investigational group will receive a Biological Vascular Graft(LineMatrix(R)) manufactured by Humatrix Medical Technology (Suzhou) Co., LTD, while the control group will receive an arteriovenous graft (GORE-INTERING(R)) manufactured by W.L. Gore & Associates, Inc. The primary endpoints are the Primary pat...